Korea Town Announces Expansion and New Vision as the Leading K-Beauty Destination in the Middle East

Korea Town Announces Expansion and New Vision as the Leading K-Beauty Destination in the Middle East

KUWAIT CITY, Kuwait, Dec. 18, 2025 /PRNewswire/ -- Korea Town, a K-beauty retail concept owned and powered by Boutiqaat, the Middle East's largest K-beauty destination, announces a renewed vision to become the most trusted global destination for...

Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE

Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE

SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting...

CYFIRMA Announces DeCYFIR 4.0: Industry-Leading AI Platform Engineered for Preemptive Protection Against Future Threats

CYFIRMA Announces DeCYFIR 4.0: Industry-Leading AI Platform Engineered for Preemptive Protection Against Future Threats

Revolutionary 9 Pillar AI Architecture Combines Threat Discovery, Intelligence, Prioritization, and Deception for Total Digital Security SINGAPORE and TOKYO, Dec. 18, 2025 /PRNewswire/ -- CYFIRMA, the global leader in Preemptive External Threat...

Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature

Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature

SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

Milesight Announces Mobile Surveillance Unit Solution Powered by Outdoor-Ready Cameras

Milesight Announces Mobile Surveillance Unit Solution Powered by Outdoor-Ready Cameras

XIAMEN, China, Dec. 18, 2025 /PRNewswire/ -- Milesight today announced its Mobile Surveillance Unit (MSU) Solution, a rapidly deployable security system built for sites with no fixed power, no fixed network, and constantly changing risks. The...

Historic production of graphene enhanced cement successfully completed

Historic production of graphene enhanced cement successfully completed

Highlights Production of 600 tonnes of low-carbon PureGRAPH® enhanced cement successfully completed by one of the UK's largest cement producers Graphene enhanced cement will be used by multiple end users in a range of applications, including...

Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting

Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting

TOKYO, Dec. 18, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, in partnership with Hitachi High-Tech Corporation (HHT) announces the presentation of high resolution structural variation data on the...

MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics

SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- MEDI&GENE, a biopharmaceutical company developing therapeutics for metabolic diseases, announced today that it has entered into a Catalyze agreement with Eli Lilly and Company (Lilly) to advance...

IFS Announces IFS Unleashed and IFS Connect series dates for 2026

IFS Announces IFS Unleashed and IFS Connect series dates for 2026

New Annual Pass launched IFS Unleashed confirmed for October 12-16, 2026 in Orlando, Fl IFS Connect series of 10 regional events starts on March 10, 2026 in Munich, Germany LONDON, Dec. 17, 2025 /PRNewswire/ -- IFS, the leading provider of...

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today...

  • 1
  • ...
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • ...
  • 157
  • menu
    menu